Strategic partnerships Teva actively pursues global licensing and collaboration opportunities, evidenced by the Polpharma Biologics deal for Ocrevus biosimilars, signaling openness to expand portfolio through in-licensing and co-development with partners.

Biosimilars growth With a global generics and biosimilars focus and recent asset acquisitions, Teva aims to strengthen its biosimilars pipeline, presenting potential cross-sell opportunities to healthcare systems seeking cost-effective biologic therapies.

Neurology and movement disorders Recent real-world data and presentations around AUSTEDO and AUSTEDO XR for tardive dyskinesia and Huntington's disease highlight Teva's emphasis on neurology and movement disorders, suggesting potential adoption opportunities in specialty neurology channels and centers of excellence.

Scale and capabilities Large workforce and global manufacturing reach combined with robust IT and ERP infrastructure (SAP, Master Data Governance, PDM) indicate Teva’s capacity to scale complex product launches, enabling rapid deployment of new formulations and generics to diverse markets.

Cost-conscious procurement Significant headcount reductions signal ongoing cost optimization while maintaining R&D and commercialization efforts, creating opportunities to approach Teva with value-based partnerships, efficiency-focused supply arrangements, and streamlined distribution solutions.